Identification of nuclear valosin-containing-protein-like as a target of anti-nuclear autoantibodies in systemic sclerosis
ObjectiveTo identify the target antigen of an anti-nuclear autoantibody (ANA) from a patient with a suspected systemic autoimmune disease and to study the autoantibody’s clinical association.MethodsThe index patient serum was screened for autoantibodies using indirect immunofluorescence assay (IFA)...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2024.1477365/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832592433381113856 |
|---|---|
| author | Zitao Zeng Ramona Miske Madeleine Scharf Yvonne Denno Anthonina Ott Stefanie Brakopp Bianca Teegen Winfried Stöcker Elise Siegert Elise Siegert Sandra Saschenbrecker Christian Probst Lars Komorowski |
| author_facet | Zitao Zeng Ramona Miske Madeleine Scharf Yvonne Denno Anthonina Ott Stefanie Brakopp Bianca Teegen Winfried Stöcker Elise Siegert Elise Siegert Sandra Saschenbrecker Christian Probst Lars Komorowski |
| author_sort | Zitao Zeng |
| collection | DOAJ |
| description | ObjectiveTo identify the target antigen of an anti-nuclear autoantibody (ANA) from a patient with a suspected systemic autoimmune disease and to study the autoantibody’s clinical association.MethodsThe index patient serum was screened for autoantibodies using indirect immunofluorescence assay (IFA) and line blots (membrane strips coated with parallel lines of different purified antigens). Immunoprecipitation with fixed HEp-2 cells followed by SDS-PAGE and MALDI-TOF mass spectrometry was used to identify the autoantigen, which was verified by competitive inhibition experiments, recombinant HEK293 cell-based IFA, and Western and line blots based on the recombinant antigen. The prevalence of autoantibodies against this antigen was studied in 693 patients with systemic autoimmune rheumatic diseases (SARD) and 150 healthy controls.ResultsThe index patient serum displayed a homogeneous nucleolar staining pattern on HEp-2 cells and monkey liver by IFA but did not react with 27 known nuclear antigens. Nuclear valosin-containing-protein-like (NVL) was identified as the ANA target antigen. Preincubation with recombinant NVL abolished the reactivity of the patient serum with HEp-2 cells in IFA. Additionally, the patient serum reacted with recombinant NVL in cell-based IFA and Western blot analysis, whereas sera from 15 healthy controls were nonreactive. Using line blots coated with recombinant NVL, anti-NVL autoantibodies were exclusively found in four out of 378 patients with systemic sclerosis, but neither in 315 patients with other SARD nor in 150 healthy controls.ConclusionThese findings indicate that autoantibodies against NVL may be a suitable marker to help narrowing the serological gap in systemic sclerosis. |
| format | Article |
| id | doaj-art-bb51752fd7514cba874e2435741aa006 |
| institution | Kabale University |
| issn | 2296-858X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-bb51752fd7514cba874e2435741aa0062025-01-21T08:36:55ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-01-011110.3389/fmed.2024.14773651477365Identification of nuclear valosin-containing-protein-like as a target of anti-nuclear autoantibodies in systemic sclerosisZitao Zeng0Ramona Miske1Madeleine Scharf2Yvonne Denno3Anthonina Ott4Stefanie Brakopp5Bianca Teegen6Winfried Stöcker7Elise Siegert8Elise Siegert9Sandra Saschenbrecker10Christian Probst11Lars Komorowski12Institute for Experimental Immunology, affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, GermanyInstitute for Experimental Immunology, affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, GermanyInstitute for Experimental Immunology, affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, GermanyInstitute for Experimental Immunology, affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, GermanyInstitute for Experimental Immunology, affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, GermanyInstitute for Experimental Immunology, affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, GermanyClinical Immunological Laboratory, Groß Grönau, GermanyClinical Immunological Laboratory, Groß Grönau, GermanyDepartment of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, GermanyBerlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, GermanyInstitute for Experimental Immunology, affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, GermanyInstitute for Experimental Immunology, affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, GermanyInstitute for Experimental Immunology, affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, GermanyObjectiveTo identify the target antigen of an anti-nuclear autoantibody (ANA) from a patient with a suspected systemic autoimmune disease and to study the autoantibody’s clinical association.MethodsThe index patient serum was screened for autoantibodies using indirect immunofluorescence assay (IFA) and line blots (membrane strips coated with parallel lines of different purified antigens). Immunoprecipitation with fixed HEp-2 cells followed by SDS-PAGE and MALDI-TOF mass spectrometry was used to identify the autoantigen, which was verified by competitive inhibition experiments, recombinant HEK293 cell-based IFA, and Western and line blots based on the recombinant antigen. The prevalence of autoantibodies against this antigen was studied in 693 patients with systemic autoimmune rheumatic diseases (SARD) and 150 healthy controls.ResultsThe index patient serum displayed a homogeneous nucleolar staining pattern on HEp-2 cells and monkey liver by IFA but did not react with 27 known nuclear antigens. Nuclear valosin-containing-protein-like (NVL) was identified as the ANA target antigen. Preincubation with recombinant NVL abolished the reactivity of the patient serum with HEp-2 cells in IFA. Additionally, the patient serum reacted with recombinant NVL in cell-based IFA and Western blot analysis, whereas sera from 15 healthy controls were nonreactive. Using line blots coated with recombinant NVL, anti-NVL autoantibodies were exclusively found in four out of 378 patients with systemic sclerosis, but neither in 315 patients with other SARD nor in 150 healthy controls.ConclusionThese findings indicate that autoantibodies against NVL may be a suitable marker to help narrowing the serological gap in systemic sclerosis.https://www.frontiersin.org/articles/10.3389/fmed.2024.1477365/fullANAanti-nuclear autoantibodiesautoimmune diseasebiomarkerdiagnosisnuclear valosin-containing-protein-like |
| spellingShingle | Zitao Zeng Ramona Miske Madeleine Scharf Yvonne Denno Anthonina Ott Stefanie Brakopp Bianca Teegen Winfried Stöcker Elise Siegert Elise Siegert Sandra Saschenbrecker Christian Probst Lars Komorowski Identification of nuclear valosin-containing-protein-like as a target of anti-nuclear autoantibodies in systemic sclerosis Frontiers in Medicine ANA anti-nuclear autoantibodies autoimmune disease biomarker diagnosis nuclear valosin-containing-protein-like |
| title | Identification of nuclear valosin-containing-protein-like as a target of anti-nuclear autoantibodies in systemic sclerosis |
| title_full | Identification of nuclear valosin-containing-protein-like as a target of anti-nuclear autoantibodies in systemic sclerosis |
| title_fullStr | Identification of nuclear valosin-containing-protein-like as a target of anti-nuclear autoantibodies in systemic sclerosis |
| title_full_unstemmed | Identification of nuclear valosin-containing-protein-like as a target of anti-nuclear autoantibodies in systemic sclerosis |
| title_short | Identification of nuclear valosin-containing-protein-like as a target of anti-nuclear autoantibodies in systemic sclerosis |
| title_sort | identification of nuclear valosin containing protein like as a target of anti nuclear autoantibodies in systemic sclerosis |
| topic | ANA anti-nuclear autoantibodies autoimmune disease biomarker diagnosis nuclear valosin-containing-protein-like |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2024.1477365/full |
| work_keys_str_mv | AT zitaozeng identificationofnuclearvalosincontainingproteinlikeasatargetofantinuclearautoantibodiesinsystemicsclerosis AT ramonamiske identificationofnuclearvalosincontainingproteinlikeasatargetofantinuclearautoantibodiesinsystemicsclerosis AT madeleinescharf identificationofnuclearvalosincontainingproteinlikeasatargetofantinuclearautoantibodiesinsystemicsclerosis AT yvonnedenno identificationofnuclearvalosincontainingproteinlikeasatargetofantinuclearautoantibodiesinsystemicsclerosis AT anthoninaott identificationofnuclearvalosincontainingproteinlikeasatargetofantinuclearautoantibodiesinsystemicsclerosis AT stefaniebrakopp identificationofnuclearvalosincontainingproteinlikeasatargetofantinuclearautoantibodiesinsystemicsclerosis AT biancateegen identificationofnuclearvalosincontainingproteinlikeasatargetofantinuclearautoantibodiesinsystemicsclerosis AT winfriedstocker identificationofnuclearvalosincontainingproteinlikeasatargetofantinuclearautoantibodiesinsystemicsclerosis AT elisesiegert identificationofnuclearvalosincontainingproteinlikeasatargetofantinuclearautoantibodiesinsystemicsclerosis AT elisesiegert identificationofnuclearvalosincontainingproteinlikeasatargetofantinuclearautoantibodiesinsystemicsclerosis AT sandrasaschenbrecker identificationofnuclearvalosincontainingproteinlikeasatargetofantinuclearautoantibodiesinsystemicsclerosis AT christianprobst identificationofnuclearvalosincontainingproteinlikeasatargetofantinuclearautoantibodiesinsystemicsclerosis AT larskomorowski identificationofnuclearvalosincontainingproteinlikeasatargetofantinuclearautoantibodiesinsystemicsclerosis |